Genera Research Ltd. participated in the symposium “Knowledge and Technology Transfer in Regenerative Medicine”, held on May 8, 2026 at the Croatian Academy of Sciences and Arts (HAZU) in Zagreb. The symposium brought together leading Croatian experts in translational and regenerative medicine to discuss the journey from scientific discovery to clinical application and commercialization, with a strong focus on innovation, intellectual property, and collaboration between academia and industry. During the symposium, presentations covered the development of Osteogrow technology, preclinical research of Osteogrow-C, advanced regenerative medicine formulations, and ongoing projects focused on bone regeneration and dental applications, including OSTEOforUNION and OSTEOproDENT®. The discussions highlighted the importance of connecting academic research, translational science, and industry collaboration in order to bring innovative regenerative medicine solutions closer to clinical practice and patients. Slobodan Vukičević, CEO of Genera Research Ltd. presented the development of Osteogrow - an innovative drug for bone regeneration. Dora Adanić, COO of Genera Research Ltd. , presented the hashtag OSTEOforUNION and OSTEOproDENT® projects. We are proud to contribute to initiatives that strengthen the path from scientific discovery to real-world medical impact.

Genera Research presented the latest progress in the preclinical and clinical development of OSTEOGROW-C at the 20th Tissue Engineering and Regenerative Medicine International Society (TERMIS) conference, held in Palma de Mallorca from April 20–24, 2026. TERMIS is one of the leading global platforms in the field of tissue engineering and regenerative medicine, bringing together scientists, clinicians, and industry experts from around the world to share advances and foster collaboration. As part of the scientific programme, Genera Research contributed to the session “Advanced biomaterials for bone regeneration”, chaired by Prof. Slobodan Vukičević (Zagreb, Croatia), Prof. Reinhard Windhager (Vienna, Austria), and Dr. Flavia Medeiros Savi (Melbourne, Australia). During the 90-minute session, key milestones in the development of OSTEOGROW technology were presented: Prof. Reinhard Windhager provided an overview of previous clinical trials using different OSTEOGROW formulations. Dr. Nikola Štoković and Dr. Natalia Ivanjko presented preclinical in vitro and in vivo studies on the OSTEOGROW-C formulation. Prof. Slobodan Vukičević concluded the session with a comprehensive overview of the discovery and development of OSTEOGROW, including the regulatory pathway toward a Phase III clinical study. The session also featured presentations from researchers across Europe, including contributions from Finland, Austria, and Italy, highlighting the latest developments in biomaterials for bone regeneration. The conference gathered more than 2,000 participants from across the globe, providing an important platform for scientific exchange and collaboration. The OSTEOGROW-C presentations attracted strong interest from the audience, particularly in the context of its potential as a first-in-class product following Phase III global clinical testing in patients with long bone fracture nonunions. Participation in TERMIS 2026 further reinforces Genera Research’s position at the forefront of regenerative medicine and orthobiologic innovation.